Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

被引:0
|
作者
Makiko Ono
Hitoshi Tsuda
Chikako Shimizu
Sohei Yamamoto
Tatsuhiro Shibata
Harukaze Yamamoto
Taizo Hirata
Kan Yonemori
Masashi Ando
Kenji Tamura
Noriyuki Katsumata
Takayuki Kinoshita
Yuichi Takiguchi
Hideki Tanzawa
Yasuhiro Fujiwara
机构
[1] National Cancer Center Hospital,Breast and Medical Oncology Division
[2] National Cancer Center Hospital,Clinical Laboratory Division, Department of Pathology
[3] National Defense Medical College,Department of Basic Pathology
[4] Center for Medical Genomics,Cancer Genomics Project, Pathology Division
[5] National Cancer,Breast Surgery Division
[6] Center Research Institute,Department of Respirology
[7] National Cancer Center Hospital,Department of Clinical Molecular Biology
[8] Graduate School of Medicine,undefined
[9] Chiba University,undefined
[10] Graduate School of Medicine,undefined
[11] Chiba University,undefined
来源
关键词
Triple-negative breast cancer; Neoadjuvant chemotherapy; Pathological complete response; Tumor-infiltrating lymphocytes; Tumor cell apoptosis;
D O I
暂无
中图分类号
学科分类号
摘要
The purpose of the present study was to identify histological surrogate predictive markers of pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC). Among 474 patients who received NAC and subsequent surgical therapy for stage II–III invasive breast carcinoma between 1999 and 2007, 102 (22%) had TNBC, and 92 core needle biopsy (CNB) specimens obtained before NAC were available. As controls, CNB specimens from 42 tumors of the hormone receptor-negative and HER2-positive (HR−/HER2+) subtype and 46 tumors of the hormone receptor-positive and HER2-negative (HR+/HER2−) subtype were also included. Histopathological examination including tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis, and immunohistochemical studies for basal markers were performed, and the correlation of these data with pathological therapeutic effect was analyzed. The rates of pCR at the primary site were higher for TNBC (32%) and the HR−/HER2+ subtype (21%) than for the HR+/HER2− subtype (7%) (P = 0.006). Expression of basal markers and p53, histological grade 3, high TIL scores, and apoptosis were more frequent in TNBC and the HR−/HER2+ subtype than in the HR+/HER2− subtype (P = 0.002 for TIL and P < 0.001 for others). In TNBC, the pCR rates of tumors showing a high TIL score and of those showing a high apoptosis score were 37 and 47%, respectively, and significantly higher or tended to be higher than those of the tumors showing a low TIL score and of the tumors showing a low apoptosis score (16 and 27%, respectively, P = 0.05 and 0.10). In a total of 180 breast cancers, the pCR rates of the tumors showing a high TIL score (34%) and of those showing a high apoptosis score (35%) were significantly higher than those of the tumors showing a low TIL score (10%) and those of the tumors showing a low apoptosis score (19%) (P = 0.0001 and 0.04, respectively). Histological grade and basal marker expression were not correlated with pCR. Although the whole analysis was exploratory, the degree of TIL correlated with immune response appear to play a substantial role in the response to NAC in TNBC.
引用
收藏
页码:793 / 805
页数:12
相关论文
共 50 条
  • [1] Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
    Ono, Makiko
    Tsuda, Hitoshi
    Shimizu, Chikako
    Yamamoto, Sohei
    Shibata, Tatsuhiro
    Yamamoto, Harukaze
    Hirata, Taizo
    Yonemori, Kan
    Ando, Masashi
    Tamura, Kenji
    Katsumata, Noriyuki
    Kinoshita, Takayuki
    Takiguchi, Yuichi
    Tanzawa, Hideki
    Fujiwara, Yasuhiro
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 793 - 805
  • [2] Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Leon-Ferre, Roberto A.
    Jonas, Sarah Flora
    Salgado, Roberto
    Loi, Sherene
    de Jong, Vincent
    Carter, Jodi M.
    Nielsen, Torsten O.
    Leung, Samuel
    Riaz, Nazia
    Chia, Stephen
    Jules-Clement, Gerome
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cockenpot, Vincent
    Lambertini, Matteo
    Suman, Vera J.
    Linderholm, Barbro
    Martens, John W. M.
    van Deurzen, Carolien H. M.
    Timmermans, A. Mieke
    Shimoi, Tatsunori
    Yazaki, Shu
    Yoshida, Masayuki
    Kim, Sung-Bae
    Lee, Hee Jin
    Dieci, Maria Vittoria
    Bataillon, Guillaume
    Vincent-Salomon, Anne
    Andre, Fabrice
    Kok, Marleen
    Linn, Sabine C.
    Goetz, Matthew P.
    Michiels, Stefan
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (13): : 1135 - 1144
  • [3] Tumor-Infiltrating Lymphocytes and Response to Platinum in Triple-Negative Breast Cancer
    Tung, Nadine M.
    Winer, Eric P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 969 - +
  • [4] Evaluation of tumor-infiltrating lymphocytes (TIL) and tumor cell apoptosis as predictive markers for response to neoadjuvant chemotherapy in triple-negative breast cancer
    Ono, M.
    Tsuda, H.
    Shimizu, C.
    Yamamoto, S.
    Shibata, T.
    Kouno, T.
    Tamura, K.
    Ando, M.
    Katsumata, N.
    KInoshita, T.
    Fujiwara, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
    Pang, Jian
    Zhou, Haiyan
    Dong, Xue
    Wang, Shouman
    Xiao, Zhi
    [J]. CLINICAL BREAST CANCER, 2021, 21 (06) : E681 - E687
  • [6] Functional mechanism on tumor-infiltrating lymphocytes in triple-negative breast cancer
    Kai, M.
    Mori, H.
    Kawaji, H.
    Kurata, K.
    Yamada, M.
    Kubo, M.
    Nakamura, M.
    [J]. BREAST, 2019, 44 : S96 - S96
  • [7] Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
    Si-Lin K.
    Kiley L.
    Kamis S.
    Iqbal J.
    Dent R.
    Sim Y.Y.
    [J]. Current Breast Cancer Reports, 2015, 7 (4) : 232 - 241
  • [8] Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
    Martin, Miguel
    Yoder, Rachel
    Salgado, Roberto
    del Monte-Millan, Maria
    Alvarez, Enrique L.
    Echavarria, Isabel
    Staley, Joshua M.
    O'Dea, Anne P.
    Nye, Lauren E.
    Stecklein, Shane R.
    Bueno, Coralia
    Jerez, Yolanda
    Cebollero, Maria
    Bueno, Oscar
    Garcia Saenz, Jose angel
    Moreno, Fernando
    Bohn, Uriel
    Gomez, Henry
    Massarrah, Tatiana
    Khan, Qamar J.
    Godwin, Andrew K.
    Lopez-Tarruella, Sara
    Sharma, Priyanka
    [J]. CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2160 - 2169
  • [9] Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer
    Leon-Ferre, Roberto A.
    Polley, Mei-Yin
    Liu, Heshan
    Gilbert, Judith A.
    Cafourek, Victoria
    Hillman, David W.
    Elkhanany, Ahmed
    Akinhanmi, Margaret
    Lilyquist, Jenna
    Thomas, Abigail
    Negron, Vivian
    Boughey, Judy C.
    Liu, Minetta C.
    Ingle, James N.
    Kalari, Krishna R.
    Couch, Fergus J.
    Visscher, Daniel W.
    Goetz, Matthew P.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (01) : 89 - 99
  • [10] Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer
    Roberto A. Leon-Ferre
    Mei-Yin Polley
    Heshan Liu
    Judith A. Gilbert
    Victoria Cafourek
    David W. Hillman
    Ahmed Elkhanany
    Margaret Akinhanmi
    Jenna Lilyquist
    Abigail Thomas
    Vivian Negron
    Judy C. Boughey
    Minetta C. Liu
    James N. Ingle
    Krishna R. Kalari
    Fergus J. Couch
    Daniel W. Visscher
    Matthew P. Goetz
    [J]. Breast Cancer Research and Treatment, 2018, 167 : 89 - 99